{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:55:46Z","timestamp":1773388546105,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.berh.2012.01.001","type":"journal-article","created":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T17:37:29Z","timestamp":1331919449000},"page":"157-165","source":"Crossref","is-referenced-by-count":76,"title":["Tocilizumab \u2013 A novel therapy for non-organ-specific autoimmune diseases"],"prefix":"10.1016","volume":"26","author":[{"given":"Lisa","family":"Kaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itzhak","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2012.01.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin 6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.berh.2012.01.001_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning expression of the human interleukin 6 receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.berh.2012.01.001_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an Il-6 signal trasnduced, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.berh.2012.01.001_bib4","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.berh.2012.01.001_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/BOR.0b013e3283456797","article-title":"The value of blocking Il-6 outside of rheumatoid arthritis: current perspective","volume":"23","author":"Murakami","year":"2011","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin 6 and soluble interleukin 6 receptors in synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like formation","volume":"11","author":"Kotake","year":"1996","journal-title":"Journal of Bone Mineral Research"},{"key":"10.1016\/j.berh.2012.01.001_bib7","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin 6 receptor antibody therapy reduces vascular endothelial growth factor production in RA","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib8","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9617","key":"10.1016\/j.berh.2012.01.001_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2012.01.001_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9617","key":"10.1016\/j.berh.2012.01.001_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2012.01.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune disease","author":"Tanaka","year":"2011","journal-title":"Febs Letters"},{"key":"10.1016\/j.berh.2012.01.001_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2443.2005.00900.x","article-title":"Essential role of STAT3 in cytokine-driven NF-kappa B-mediated serum amyloid A gene expression","volume":"10","author":"Hagihara","year":"2005","journal-title":"Genes to Cells"},{"issue":"7","key":"10.1016\/j.berh.2012.01.001_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/ard.2008.099267","article-title":"Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor antibody treatment","volume":"68","author":"Nishida","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.01.001_bib15","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","article-title":"Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis","volume":"54","author":"Okuda","year":"2006","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant cell arteritis with methotrexate and prednisone: a randomized double-blind placebo- controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.berh.2012.01.001_bib17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoid \u2013resistant or relapsing Takayasu arteritis with methotrexate","volume":"37","author":"Hoffman","year":"1994","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib18","first-page":"S23","article-title":"Laboratory investigation useful in giant cell arteritis and Takayasu\u2019s arteritis","volume":"21","author":"Salvarani","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra022694","article-title":"Medium and large vessel vasculitis","volume":"349","author":"Weyand","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2012.01.001_bib20","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL6 blockade","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Medical Weekly"},{"key":"10.1016\/j.berh.2012.01.001_bib21","article-title":"Tocilizumab: a novel therapy for patients with large vessel vasculitis","author":"Salvarani","year":"2011","journal-title":"American College of Rheum Annual Scientific Meeting"},{"key":"10.1016\/j.berh.2012.01.001_bib22","article-title":"Tocilizumab for the treatment of large vessel vasculitis (Giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica: a case series","author":"Unizony","year":"2011","journal-title":"American College of Rheum Annual Scientific Meeting"},{"key":"10.1016\/j.berh.2012.01.001_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000030185.67510.C0","article-title":"Tissue and serum angiogenic activity is associated with low prevalence of ischemic complication in patients with giant cell arteritis","volume":"106","author":"Cid","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2012.01.001_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","article-title":"Disease pattern in cranial and large vessel giant cell arteritis","volume":"42","author":"Brack","year":"1999","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3899\/jrheum.091185","article-title":"Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica","volume":"37","author":"Hagihara","year":"2010","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib26","first-page":"256","article-title":"Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis","volume":"40","author":"Arimura","year":"1993","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.berh.2012.01.001_bib27","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/rheumatology\/ker222","article-title":"Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody","volume":"50","author":"Sumida","year":"2011","journal-title":"Rheumatology"},{"issue":"Suppl. 64","key":"10.1016\/j.berh.2012.01.001_bib28","first-page":"S133","article-title":"Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis","volume":"29","author":"Sumida","year":"2011","journal-title":"Clininal Experimental Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib29","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10067-009-1218-8","article-title":"High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia","volume":"28","author":"Antonelli","year":"2009","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib30","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1002\/art.25003","article-title":"Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia","volume":"60","author":"Antonelli","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib31","article-title":"Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis","author":"Cohen","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.01.001_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0923-1811(95)00439-4","article-title":"Interleukin-6 (IL-6) in patients with Beh\u00e7et\u2019s disease","volume":"11","author":"Yamakawa","year":"1996","journal-title":"Journal of Dermatology Science"},{"key":"10.1016\/j.berh.2012.01.001_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clineuro.2009.02.001","article-title":"CSF levels of cytokines in neuro-Behcet\u2019s disease","volume":"111","author":"Borhani Haghighi","year":"2009","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/j.berh.2012.01.001_bib34","article-title":"Borhani Haghighi A. Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report","author":"Shapiro","year":"2011","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1016\/j.berh.2012.01.001_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","author":"Hirano","year":"2011","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/ken468","article-title":"Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis","volume":"48","author":"Kawai","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2990.1998.00092.x","article-title":"Local expression of cytokines in idiopathic inflammatory myopathies","volume":"24","author":"Lepidi","year":"1998","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.berh.2012.01.001_bib39","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","article-title":"IL-6\/BSF-2 functions as a killer helper factor in the in\u00a0vitro induction of cytotoxic T cells","volume":"141","author":"Okada","year":"1998","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.berh.2012.01.001_bib40","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib41","first-page":"308","article-title":"Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis","volume":"25","author":"Hasegawa","year":"1998","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"Journal of Dermatology Science"},{"key":"10.1016\/j.berh.2012.01.001_bib43","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib44","first-page":"1207","article-title":"Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma","volume":"19","author":"Feghali","year":"1992","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.berh.2012.01.001_bib46","first-page":"16","article-title":"Urinary levels of IL-6 in patients with active lupus nephritis","volume":"40","author":"Iwano","year":"1993","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.berh.2012.01.001_bib47","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib48","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0889-857X(05)70039-9","article-title":"Prognosis, course of disease, and treatment of the spondyloarthropathies","volume":"24","author":"Leirisalo-Repo","year":"1998","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"12","key":"10.1016\/j.berh.2012.01.001_bib50","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.24899","article-title":"Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"61","author":"Tanaka","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.berh.2012.01.001_bib51","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases","volume":"65","author":"Francois","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.01.001_bib52","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jbspin.2010.09.011","article-title":"Short-term effect of IL-6 inhibition in spondylarthritis","volume":"77","author":"Wendling","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2012.01.001_bib53","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1136\/ard.2009.126706","article-title":"Mixed response to tocilizumab for ankylosing spondylitis","volume":"69","author":"Henes","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.berh.2012.01.001_bib54","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3899\/jrheum.110265","article-title":"Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab","volume":"38","author":"Cohen","year":"2011","journal-title":"Journal of Rheumatol"},{"key":"10.1016\/j.berh.2012.01.001_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s002960050111","article-title":"Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis","volume":"19","author":"Elkayam","year":"2000","journal-title":"Rheumatology International"},{"key":"10.1016\/j.berh.2012.01.001_bib56","article-title":"Psoriatic arthritis in two patients with inadequate response to treatment with tocilizumab","author":"Ogata","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.berh.2012.01.001_bib57","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocular Immunology and Inflammation"},{"key":"10.1016\/j.berh.2012.01.001_bib58","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood-2007-05-091074","article-title":"Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease","volume":"110","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.berh.2012.01.001_bib59","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","article-title":"Tocilizumab for the treatment of steroid refractory graft-versus-host disease","volume":"17","author":"Drobyski","year":"2011","journal-title":"Biology of Blood Marrow Transplantation"},{"issue":"21","key":"10.1016\/j.berh.2012.01.001_bib60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10165-010-0411-6","article-title":"Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab","volume":"2011","author":"Nishida","year":"2011","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.berh.2012.01.001_bib61","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.30215","article-title":"Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab","volume":"63","author":"Vaitla","year":"2011","journal-title":"Arthritis & Rheumatism"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694212000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694212000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T02:13:25Z","timestamp":1687313605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694212000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1521694212000022"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2012.01.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}